DISP-31. GLOBAL MAPPING OF CAR-T THERAPY CLINICAL TRIALS FOR ADULT PATIENTS WITH CNS TUMORS

Abstract BACKGROUND Despite increasing global interest in expanding access to neuro-oncology clinical trials, the distribution and availability of CAR-T cell therapy trials targeting central nervous system (CNS) tumors remain poorly defined. Glioblastoma patients face significant financial toxicity due to the high costs of treatment, travel, and supportive care, which may further limit participation in cutting-edge clinical trials. This study aims to analyze the global landscape of CAR-T clinical trials for CNS tumors in adults, with attention to regional disparities and the financial accessibility of such trials. METHODS We will include interventional studies registered in the International Clinical Trials Registry Platform (ICTRP) that involve adult patients (≥18 years) diagnosed with CNS tumors. Systematic searches of ICTRP, PubMed, and Google Scholar will be used to identify trials and peer-reviewed manuscripts reporting trial results. Variables of interest include the total number of neuro-oncology trials, inclusion criteria, geographical distribution, sponsorship sources, and any reported provisions addressing financial burden or patient support. RESULTS Findings will reveal global patterns in CAR-T trial availability and highlight any disparities between high-income countries (HICs) and low- and middle-income countries (LMICs). Preliminary analysis is expected to show a concentration of CAR-T clinical activity in HICs, with minimal presence in LMICs. Furthermore, few trials may provide financial assistance or address the economic burden faced by participants, particularly those diagnosed with glioblastoma, a population already at risk for significant financial toxicity. CONCLUSIONS This study offers a comprehensive overview of the global CAR-T trial landscape for CNS tumors and emphasizes the need for more inclusive and economically accessible neuro-oncology research. Addressing both regional and financial barriers especially for glioblastoma patients is critical to ensuring equitable access to promising innovations in immunotherapy.